Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is it even possible to bring back the discussion to what matters:
the company's products and not personalities.
Is Rituximab now dead? How about the other clones and insulin clone.
How can anyone ever buy into this company when we have all this infighting. It is really time to stop talking about characters and focus more on what the company makes. Even with all the bickering going on, don't we all want the share price to go up?
Is there anything left of this company? I do not want to hear character attacks on either side of the bickering. Just trying in vain to bring back discussion to what a real discussion board should be about.
could you elaborate
I hope it is some good news.
do you have some link, please?
That is a very pessimistic outlook.
That is a good statement.. do you have any reference?
any update on future direction ?
is there expansion into other diseases besides eye diseases?
ACTC is still the best stem cell stock on the market.
How do you know that?
any explanation why the price is declining?
why do you think it is declining over the past 2 weeks?
what article are we waiting for?
why would you say that about Dr. Lanza. I thought he was an asset to the company.
any movement upwards is satisfactory for me. The baseline price of $ 0.07 has not changed for a while. what article in New England Journal of medicine was relevant to ACTC? any one ?
I do have a subscription.. why?
I don't see any link between these companies.. to be credible, a sound and solid link and source should be provided.
Some of these companies you listed are due for suspension due to lack of filing.
News.. Reuters:
Zhejiang Huahai Pharmaceutical Co Ltd Announces Cooperation with ONCOBIOLOGICS
Monday, 6 May 2013 08:00pm EDT
Zhejiang Huahai Pharmaceutical Co Ltd announced that it will sign agreements with ONCOBIOLOGICS, regarding the strategic alliance, cooperative management, joint venture, joint development and technology license on biotechnology medicines. According to the agreements, the Company will receive licenses on four kinds of biological medicines and will set up a joint venture in the United States for joint development of the biological medicines. The Company and ONCOBIOLOGICS will also set up a joint venture in China, which will be engaged in research and development of biological medicines and application of technologies.
This would be great for Viropro.
Companies run their operations based on a vision and a solid plan for future. You would not announce every little step you make just because a few people , who do not own the stock, asked for them.
This is a company run by experts in finances, have their experienced corporate lawyers, know the laws of the different countries they have their branches on.
There is absolutely nothing pending before SEC regarding Viropro.
Information like that, designbed to bring down share prices, is inaccurate and misleading.
Even the so called true stories are untrue about viropro. There will be PR and announcementa at the times of Cynthia's choosing.
A company of visionaries do not plan their future based on demands coming from obscure sources. We cannot compare viropro to petty penny companies that were fraudulant to say the least. This company has a series of biosimilar giants, and do not forget insulin.
My guess is that insulin will be the next deal coming out from some of cynthias trip. I do not have any insider information. But given the fact, that insulin was never mentioned with oncobiologics, it will be a next mega deal.
This company cannot be brought down by untrue stories or fear or panic.
People who have solid nerves, entrust their money with a visionary CEO, will soon reap the benefits of their good investment.
Viropro is eligible for giant outcomes to come soon. A deal should be imminent, I speculate it would be insulin.
Viropro is a voluntary filer. PERIOD. Any inquiry about that is irrelevant. This has been communicated to all shareholders according to SEC regulations that FACEBOOK can be used for official communications by companies. VIROPRO has TERMS of USE just like iHUb has its own. Just Like messages here get deleted if the TOS violated, the same for Viropro facebook. I do not see anything different. No company would let its facebook be used to repeat a question 1 millions times when the company has resolved the issue once for all. Case closed. Any more inquiry about filing on facebook will be deleted and correctly so. Especially inquiries coming from individuals that do not own the stock.
Viropro has been doing advances in deals and manufacturing plants for manufacturing biosimilars. The CEO of the company sets priorities, allocates finances to operations she deems essential.
Outside stories do not tell the whole picture. Obscure web sites with emblems and symbols do not tell the story of a company coming of age and penetrating markets of south asia.
When a capable ceo tells you the status of financials and being current or not, that should be trusted. One can discuss those on facebook page so the company can answer directly.
We will see how the share price would answer in June.
News:
Malaysia aims to be a biopharm hub
Published on: Friday, April 26, 2013
CHICAGO: Malaysia is positioning itself as a biopharmaceutical hub producing cost-competitive medicine, especially for the underserved emerging markets following joint-venture initiatives clinched with foreign firms at the renowned gobal bio-technology conference here.
The partnerships include the manufacture of low-cost cancer drugs, the distribution of insulin and insulin-related products, setting up a biotech facility in Nusajaya and producing lower cost biopharmaceutical products.
The four projects were announced at the Bio Chicago 2013, where Malaysia through the Malaysian Biotechnology Corporation is again taking an active part.
The first partnership between Viropro and Oncobiologics will see an investment of US$83 million where Viropro and its subsidiary, Alpha Biologics, will have the rights to manufacture six monoclonal antibody products developed by Oncobiologics to be marketed in more than 70 countries.
Viropro chairman Cynthia Ekberg Tsai said the partnership would lead to accessibility and affordability of critical care cancer medicine to patients.
"We choose Malaysia because the government is very visionary and understands the importance of biologics medicine. We see tremendous IP (intellectual property) protection, skilled work force and resource-rich country with continuous energy that is very important for us," she told reporters here.
Tsai said the construction for the manufacturing facilities would start by June, and expected to start production by 2014.
Viropro also established relationship with GL Rapha for lower cost biopharmaceutical products including the activities of technology transfer, licensing, marketing and distribution.
Another company, CCM Pharmaceuticals Sdn Bhd has secured an exclusive licence and distribution rights from Biocon Ltd India to market, sell and distribute a range of insulin products in Malaysia and Brunei.
Its director Leonard Ariff Abd Shatar said the partnership was expected to bring value to the local insulin market in Malaysia and Brunei which is valued at RM90 million.
Meanwhile, Malaysian Bio-Xcell Sdn Bhd signed a collaboration deal with Agila Biotech to build a next-generation, state-of-the-art biotech facility in Nusajaya, Johor.
Chief executive officer Rizatuddin Ramli said the initial investment was about US$35 million.
Construction on the project has started on a 3.2-hectare land and Bio-Xcell expects to employ 150 high-skilled workers. - Bernama
The real explosion of the stock price (VPRO) would come when Insulin contracts are signed.
Based on prevalence of diabetes here and worldwide , the price tag on an an insulin clone could surpass all the other biosimilar antibodies combined.
After Sanofi, Lilly, and Novo, Viropro would be the first company ever to bioengineer insulin analgues and market them. Even after patent expiration of all Lilly and Novo insulins, no company has been able to clone them.
I wish the company revealed more about its insulin capabilities. They have mentioned only snippets of info about its insulin program. Any one knows more?
News release regarding Viropro
Biotech sector gets global boost
Rozana Sani
bt@mediaprima.com.my
2013/04/24
THE Malaysian biotechnology industry looks set to experience a significant growth with the global launch of
the nation's Bioeconomy Transformation Programme (BTP) at the BIO Chicago 2013.
The launch was sweetened with the announcement of some US$130 million (RM400 million) in potential
investments from four joint ventures.
The pacts were unveiled during the opening of the Malaysian Pavilion at the Biotechnology Industry
Organisation (BIO) Convention and Exhibition, here, yesterday.
"The partnerships and collaborations magnify the value proposition that Malaysia offers - that the country is
attractive, especially in nurturing and driving global entrepreneurship and partnerships with foreign
companies," said Datuk Dr Mohd Nazlee Kamal, chief executive officer of Malaysian Biotechnology Corp
(BiotechCorp) - the lead development agency for the local biotech industry. "These collaborations are clear
endorsements of Malaysia's growing importance in the global ecosystem of bio-based industries." The BTP is
a platform provided by the government for the private sector to channel and maximise commercial
opportunities in bio-based industries.
To date, Malaysia is the second country in the Asia Pacific region after China to announce such an initiative.
The four collaborations include a manufacturing alliance between Malaysia's Alpha Biologics/Viropro and
US-based Oncobiologics to produce high-quality, low-cost cancer drugs for 75 emerging market countries
(excluding China), and a licensing and distribution agreement between CCM Pharmaceutical Sdn Bhd and
India-based Biocon to enable the former to register the Rh Human Insulin and Insulin Glargin.
The other two are between Malaysian Bio-XCell and India-based Agila Biotech, and between Alpha
Biologics/Viropro and South Korean company GL Rapha.
Alpha Biologics/Viropro and GL Rapha inked a pact on lower cost biopharmaceutical products, with focus on
Malaysia and IndoChina.
Bio-Xcell and Agila, meanwhile, will set up a customised biotech facility located in the Bio-XCell Malaysia
ecosystem in Nusajaya, Johor.
BiotechCorp expects its ninth participation in the BIO International Convention and Exhibition to help drive
the country's bioeconomic growth.
"With the global launch of the BTP, we are now entering a new dimension where bioeconomy will become
the pull factor for global investments into Malaysia," Nazlee said. One of the main components in realising
the vast potential within the BTP is the biomedical sector.
1/2
Malaysia's pharmaceutical/biopharma market reached RM4.21 billion in 2011 and is expected to grow to
RM6.3 billion in 2015 at a compounded annual growth rate, or CAGR, of 8.5 per cent. This is encouraging,
considering the Asia Pacific biotechnology market is growing at a CAGR of 10.88 per cent per annum
(2010-2015). Next year, at the BIO San Diego 2014, Nazlee hopes more bio-agriculture deals will transpire.
The BIO International Convention and Exhibition is the world's largest gathering of biotechnology
professionals, business leaders, scientists and policy makers.
The event, which started on Monday and ends tomorrow, is estimated to draw more than 16,500 attendees and
1,700 exhibitors from 65 countries.
Viropro responds in a strong and firm tone to recent arguments about SEC/ share price: from Facebook/ viropro:
1.
Viropro To make it very clear, the Officers and Directors of Viropro are committed to Viropro, as a publicly-traded company, and are working diligently (24/7/365) to increase share value for each and every one of its shareholders - no matter how big or small the shareholder. We are very open to a free exchange of ideas about the company as long as they are true and accurate. However, there is no place for inaccurate information, particularly deliberate disinformation. It is counterproductive to shareholder value. Persons who cannot abide by this fundamental rule will be blocked from this site
2. Further, Viropro is fully compliant with SEC regs. Viropro is currently a voluntary filer.
The second response should satisfy expediter.
Any prediction for share price for the next week?
this piece of news about alpha biologics has been removed from viropros web site. why?
you exaggerate and dramatize a lot. Viropro is not your lousy software company operating from a rundown garage.
Oncobiologics has a deal with viropro, is that also a scam?
You have been rehashing the same point but with drama. I also posted I am worried but I am not accusing viropro of fraudulent conduct. Your posts just harm this stock. You should tone it down.
when there is no news, even our posts are just venting frustration of waiting. It has been 27 months for me. Where is True Story?
When OTC Magic twitter came out, I thought we would have volumes of over 2 M a day. It seems it had an opposite effect, zero volume for 2 days. Strange. What kind of an alert was that?
We should predict a lot of frustration on here and other boards if financials are not filed. Even "True Story" posted once that financials will be out by end of March.
I don't know what other priorities Cynthia has. Even if she does have other priorities, the company would look stronger with financial rather than without. I wish they finished the financials ASAP.
more press but lower price !!
http://www.sbwire.com/press-releases/viropro-inc-pinkvpro-making-its-way-to-more-markets-220730.htm
Viropro, Inc. (PINK:VPRO) Making Its Way to More Markets
Las Vegas, NV -- (SBWIRE) -- 03/11/2013 -- Viropro, Inc. (PINK:VPRO) signed biosimilar collaboration agreement to produce six monoclonal antibody products. These products are manufactured by Oncobiologics and sold in seventy countries.
The agreement provides Viropro Inc with exclusive rights to sell biosimilars in Malaysia. The product, six biosimilars are broad versions of Humira®, Rituxan®, Avastin®, Herceptin®, Erbitux®. These are known as best known therapies in treating respective cancer and immune diseases. The products earn about $40 billion annual global revenue.
Viropro Inc(Viropro) operates in delivery of technologies related to industrial production of biogeneric therapeutic proteins. The technology treats cancer, diabetes, hepatitis or multiple sclerosis. The company researches to offer treatment for undealt medical problems. The company focuses on markets of South America, Northern Africa and Asia.
To find out what OTCMAGIC projects for Viropro, Inc. for both short term and long term please click here: VPRO
OTCMAGIC Spends all day scouring the markets for the next huge Penny Stock Winner. Investors have come to trust us for our up to date commentary on all hot stocks so please visit OTCMAGIC right now and see what it’s all about for yourself! At 30,000 Visitors a Month and growing rapidly OTCMAGIC is the hottest thing in stock picks!
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PLEASE NOTE: OTCMagic.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://OTCMagic.com/disclaimer. Release of Liability: Through use of this website viewing or using you agree to hold OTCMagic.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. OTCMagic.com affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCMagic.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCMagic.com. We make no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to buy or sell any securities. Any claims or Statements should be deemed hypothetical. OTCMagic.com, nor any of its affiliates are not registered investment advisors or broker dealers.
Media Relations Contact
Marco Magic
775-581-4290
Email | Web
Follow OTCMAGIC:
Share on rss
Source: OTCMAGIC
Posted Monday, March 11, 2013 at 12:26 PM CDT - Permalink
Maybe new buyers either through Cynthia. I don't see that the twitter article brought anything today. But maybe it is too early.
The good thing is the narrow spread, which is consistent.
Spread has been persistently narrow, but MMs are not giving any shares away.
doe any one of the long-term investors know what was the size of the dilution? I have asked this many times, no one answers.
I know you are afraid of SEC sanctions (= shut down trading), but in worst scenario, trading would resume when you finish financing.
Let's enjoy a little bit the 7% gain we had today and narrowing of spread of bid/sell of this stock. Finally good days are on horizon after 2 years of waiting. My investment is now long-term. This is the first time in my life I have a stock that is not short term.
That means with a big gain, I would pay only capital gain tax and not 39.6% tax.
From Viropro.com:
Alpha Biologics SDN Receives Best Practices Award from Frost & Sullivan
in Uncategorized | by PR Relations | No Comments
FROM FROST & SULLIVAN: “The Frost & Sullivan Best Practices team of industry experts presents awards to companies demonstrating best practices in a variety of regional and global markets. These Best Practices Awards recognize the superior planning and execution of product launches, strategic alliances, distribution strategies, technological innovations, customer service, and mergers and acquisitions.
Its my great pleasure to inform you that ALPHA BIOLOGICS SDN. BHD. HAS BEEN NOMINATED FOR THE MALAYSIA ENTREPRENEURIAL BIOTECH COMPANY OF THE YEAR AWARD. . Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which increases customer acquisition and overall market penetration potential.”
How many new shares were added by the company? any one has an answer?
sorry, I meant jan 6 2011
I have a huge position on VPRO. I am not planning any buy or sell until at least $ 0.1. I do not have any hidden agenda when I comment. I have been in since the spectrum pseudo-deal.i.e since jan 6 2010. This is a dialogue. We cannot agree on everything. But we all agree that the stock has a bright future.